Skip to content

Lantheus

US · LNTH #1847 by market cap Listed 2015
102.10 0.00 0.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Valuation each multiple against its own 5-year range

P/B ratio 4.90 Cheap vs history 26th percentile
5-year average 6.57 · #55 of 69 in Drug Manufacturers - Specialty & Generic
P/E ratio 25.27 Expensive vs history 68th percentile
5-year average 11.97 · forward 16.11 · #16 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 4.25 In line with history 50th percentile
5-year average 4.75 · forward 4.08 · #52 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Lantheus (LNTH) 6.68B 25.40 4.93 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value91.04 Economic moatNarrow UncertaintyHigh

Trading 10.8% above Morningstar's fair value estimate.

Fair value

Lantheus Holdings Inc is assigned a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 12% premium over our quantitative fair value estimate of $91.04 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's unfavorable dividend structure undermines our valuation estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. For example, the firm's forward dividend yield of 0% falls in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 20.6%, a core component of valuation, lies in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 20:01:26 · For reference only, not investment advice and not tailored to your situation.

Lantheus discussion 0 comments

Add a comment